Compare SYRE & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYRE | BHC |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 2015 | 1996 |
| Metric | SYRE | BHC |
|---|---|---|
| Price | $40.36 | $5.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $55.57 | $8.33 |
| AVG Volume (30 Days) | 663.5K | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 423.08 |
| EPS | N/A | ★ 0.42 |
| Revenue | N/A | ★ $8,724,000,000.00 |
| Revenue This Year | N/A | $4.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $14.10 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.91 | $4.28 |
| 52 Week High | $45.76 | $8.69 |
| Indicator | SYRE | BHC |
|---|---|---|
| Relative Strength Index (RSI) | 58.28 | 40.10 |
| Support Level | $14.62 | $5.52 |
| Resistance Level | $45.76 | $7.13 |
| Average True Range (ATR) | 2.32 | 0.29 |
| MACD | 0.25 | 0.02 |
| Stochastic Oscillator | 58.76 | 31.10 |
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.